Drugs / FXI-GalNAc-siRNA
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05844293 | May 2023 → May 2024 | factor XI deficiency | Sirnaomics | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | FXI-GalNAc-siRNA | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05844293 ↗ |
| Modality | Small interfering RNA (siRNA) | “FXI-GalNAc-siRNA” NCT05844293 ↗ |
| Route | Subcutaneous | “when administered subcutaneously” NCT05844293 ↗ |